On Tuesday, Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) opened higher 1.97% from the last session, before settling in for the closing price of $16.25. Price fluctuations for TEVA have ranged from $12.51 to $22.80 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -0.32% over the last five years. Company’s average yearly earnings per share was noted 4.45% at the time writing. With a float of $1.13 billion, this company’s outstanding shares have now reached $1.13 billion.
The firm has a total of 36167 workers. Let’s measure their productivity. In terms of profitability, gross margin is 48.77%, operating margin of 8.4%, and the pretax margin is -7.76%.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Teva- Pharmaceutical Industries Ltd. ADR is 0.02%, while institutional ownership is 59.47%. The most recent insider transaction that took place on Feb 18 ’25, was worth 1,279,661. Before that another transaction happened on Feb 12 ’25, when Company’s See “Remarks” sold 177,626 for $16.25, making the entire transaction worth $2,886,565. This insider now owns 204,964 shares in total.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 4.45% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.67% during the next five years compared to -9.62% drop over the previous five years of trading.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Trading Performance Indicators
Check out the current performance indicators for Teva- Pharmaceutical Industries Ltd. ADR (TEVA). In the past quarter, the stock posted a quick ratio of 0.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.14. Likewise, its price to free cash flow for the trailing twelve months is 9.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.45, a number that is poised to hit 0.51 in the next quarter and is forecasted to reach 2.83 in one year’s time.
Technical Analysis of Teva- Pharmaceutical Industries Ltd. ADR (TEVA)
Analysing the last 5-days average volume posted by the [Teva- Pharmaceutical Industries Ltd. ADR, TEVA], we can find that recorded value of 13.23 million was better than the volume posted last year of 13.13 million. As of the previous 9 days, the stock’s Stochastic %D was 18.44%. Additionally, its Average True Range was 0.68.
During the past 100 days, Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) raw stochastic average was set at 7.29%, which indicates a significant decrease from 13.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.07% in the past 14 days, which was higher than the 53.38% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.59, while its 200-day Moving Average is $17.80. Now, the first resistance to watch is $17.03. This is followed by the second major resistance level at $17.49. The third major resistance level sits at $17.84. If the price goes on to break the first support level at $16.23, it is likely to go to the next support level at $15.88. Should the price break the second support level, the third support level stands at $15.42.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Key Stats
There are currently 1,132,909K shares outstanding in the company with a market cap of 18.79 billion. Presently, the company’s annual sales total 16,544 M according to its annual income of -1,639 M. Last quarter, the company’s sales amounted to 4,229 M and its income totaled -218,000 K.
